Xeris Biopharma Holdings Return on Equity

Xeris Biopharma Holdings (XERS) currently reports a ROE of 176.34%. That is above the Healthcare sector average of -75.84%. Use the charts on this page to explore Xeris Biopharma Holdings's ROE history and peer comparisons.

Xeris Biopharma Holdings's ROE of 176.34% is higher than the Healthcare sector average of -75.84%. That is roughly 332.5% above the sector mean. A reading higher peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' ROE, but Xeris Biopharma Holdings's current 176.34% should be judged against Healthcare norms (sector average: -75.84%) and against XERS's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current ROE of 176.34%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is -75.84%. From there, open related valuation or income-statement pages for Xeris Biopharma Holdings, and consider following XERS for alerts when major investors trade the stock.

Xeris Biopharma Holdings is classified in the Healthcare sector. On ROE, it currently shows 176.34% versus a sector average near -75.84%. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing XERS with unrelated industries.